Physician profile
Laura Jetter
NPI 1467964056
$3,885.02
in general payments reported to CMS, 2019-2025
29 companies · $1,174 in 2025
The $1,174 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $498 · 2022: $580 · 2023: $693 · 2024: $940 · 2025: $1,174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,337 · Education: $471.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,336.52 |
| Education | $470.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $952.39 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $833.46 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $432.36 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $211.51 | 2021-2025 | Takhzyro, Hyqvia |
| Glaxosmithkline, LLC. | $207.67 | 2021-2025 | Nucala, Trelegy Ellipta |
| Genentech USA, INC. | $200.50 | 2021-2025 | Xolair |
| Pfizer INC. | $122.10 | 2021-2024 | |
| Alk-Abello, INC | $115.88 | 2021-2024 | Standardized Mite D. Farinae, Alternaria Tenuis, Timothy, Standardized |
| Regeneron Healthcare Solutions, INC. | $89.58 | 2024-2025 | Dupixent |
| Amgen INC. | $87.58 | 2021-2023 | Tezspire |
| Novartis Pharmaceuticals Corporation | $72.60 | 2021-2025 | |
| Csl Behring | $71.78 | 2023-2024 | Hizentra |
| Galderma Laboratories, L.P. | $60.44 | 2024-2025 | Nemluvio |
| Pharming Healthcare, INC. | $52.10 | 2022-2025 | Ruconest |
| Biocryst US Sales Co., LLC | $51.92 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $50.02 | 2021-2022 | |
| Incyte Corporation | $42.97 | 2022-2023 | Opzelura |
| Atricure, INC. | $33.94 | 2025 | Atricure Cryoice Cryosphere Cryoablation System |
| Teva Pharmaceuticals USA, INC. | $31.79 | 2021 | |
| Optinose US, INC. | $30.92 | 2023-2024 | |
| Grifols USA, LLC | $24.69 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $17.40 | 2025 | Neffy |
| Horizon Therapeutics Plc | $16.26 | 2021 | |
| Blueprint Medicines Corporation | $14.44 | 2025 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.07 | 2021 | |
| Verona Pharma, INC. | $13.53 | 2025 | Ohtuvayre |
| Uswm, LLC | $13.00 | 2021 | |
| Mylan Specialty L.P. | $12.52 | 2021 | |
| Organon LLC | $7.60 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Jetter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.